Ann: Chair's Address to Shareholders, page-3

My biggest takeaway from the above statement...

Even with this transformation, we have remained steadfast in advancing the critical
development steps for our lead asset, SNT-5505, which sits at the heart of our
pipeline and embodies the promise of our work. Our phase 2 trial in myelofibrosis
has achieved full recruitment, a milestone that strengthens the foundation of our
ongoing hematology program.
Additionally, we were pleased to report that we successfully attracted non-dilutive funding for two new studies focused on
myelodysplastic syndrome (MDS), which are slated to begin next year. This funding
is a significant achievement that highlights the externally recognised value and
potential of SNT-5505, ensuring that we continue to invest in our science
while respecting our shareholders’ interests


Enjoy the Day ,,NZT